{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-25-000006","form_type":"8-K","ticker":"BGLC","cik":"0001737523","company_name":"BioNexus Gene Lab Corp","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.666559+00:00","generated_at":"2026-05-28T18:41:03.261472+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split","bullets":["Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.","Company intends to effect a reverse stock split by April 7, 2025 if needed.","Effective Jan 30, 2025, Nasdaq requires 10-day prior notice of reverse split details, including shareholder approval date.","Failure to comply by May 1, 2025 will result in delisting from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-25-000006","json":"https://secwatch.observer/filing/0001477932-25-000006.json","markdown":"https://secwatch.observer/filing/0001477932-25-000006.md","text":"https://secwatch.observer/filing/0001477932-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225000006/0001477932-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225000006/bglc_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:41:03.261472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7f2b4916346c58647f8ec46812b33dd600135c9","claim":"BioNexus Gene Lab Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"December 27, 2024, BioNexus Gene Lab Corp. (the “Company”) received a written notice from the Nasdaq Hearings Panel (the “Panel”) indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the “Bid Price Rule”). The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1737523/000147793225000006/0001477932-25-000006-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}